Skip to main content

Table 1 Distribution of the studied cases (n = 30) according to primary malignancy and clinical manifestations

From: Brain metastases assessment by FDG-PET/CT: can it eliminate the necessity for dedicated brain imaging?

  Patients no. (n = 30) %
Primary
Unknown 18 60.0
  Primary identified by PET-CT   
   Bronchogenic 10 33.3
   Renal cell carcinoma 2 6.7
   Lymphoma 2 6.7
  Unidentified 4 13.3
Known 12 40.0
  Bronchogenic 5 16.7
  Breast cancer 3 10.0
  Melanoma 2 6.7
  Renal cell carcinoma 1 3.3
  Papillary thyroid carcinoma 1 3.3
Neurological symptoms
 Free 14 46.7
 Headache 12 40.0
 Hemi paresis 2 6.7
 Disturbed level of consciousness 2 6.7
Systemic metastases
 Bony 12 40.0
 Nodal 10 33.3
 Lung 8 26.7
 Suprarenal 4 13.3
 Hepato-splenic 2 6.7
 Subcutaneous 2 6.7
 None 14 46.7